Race for Coronavirus vaccine: U.S. to pay Pfizer, BioNTech $1.95 bln for millions of COVID-19 vaccine doses

By: |
Published: July 22, 2020 6:21 PM

Pfizer Inc and German biotech firm BioNTech SE will get $1.95 billion from the U.S. government to produce and deliver 100 million doses of their COVID-19 vaccine candidate

coronavirus vaccine update todayCoronavirus vaccine update today: The agreement allows the U.S. government to acquire an additional 500 million doses. Reuters

Pfizer Inc and German biotech firm BioNTech SE will get $1.95 billion from the U.S. government to produce and deliver 100 million doses of their COVID-19 vaccine candidate, the companies said on Wednesday. The agreement allows the U.S. government to acquire an additional 500 million doses, the Department of Health and Human Services and the Department of Defense said.

The Trump administration has agreed to spend billions of dollars for the development and procurement of a potential vaccine. The administration launched ‘Operation Warp Speed’ — a joint HHS and Department of Defense program — to accelerate the development of coronavirus vaccines, treatments and diagnostics.

More than 150 coronavirus vaccines using a variety of technologies are in development globally, with some two dozen already in human trials. Governments have signed deals with drugmakers to secure the supply of various vaccine candidates.

The aim is to produce vaccines that can end the pandemic by protecting billions of people from infection or severe illness.

Pfizer and BioNTech’s vaccine candidate is among those that are set to be tested in a large trial. The vaccine has shown promise in early-stage small studies in humans.

Pfizer will deliver the doses if the product receives Emergency Use Authorization or licensure from the U.S. Food and Drug Administration, after completing demonstration of safety and efficacy in a large Phase 3 clinical trial.

The companies said they expect to be ready to seek some form of regulatory approval as early as October, if the ongoing studies are successful.

Pfizer and BioNTech currently expect to manufacture up to 100 million doses globally by the end of 2020, and potentially more than 1.3 billion doses by the end of 2021, subject to final dose selection from their clinical trial.

Pfizer’s shares rose 4%, while BioNTech’s U.S.-listed shares were up about 6% before the bell.

Get live Stock Prices from BSE, NSE, US Market and latest NAV, portfolio of Mutual Funds, calculate your tax by Income Tax Calculator, know market’s Top Gainers, Top Losers & Best Equity Funds. Like us on Facebook and follow us on Twitter.

Financial Express is now on Telegram. Click here to join our channel and stay updated with the latest Biz news and updates.

Next Stories
1First-of-its-kind mobile COVID-19 lab dedicated to public
2Tamil Nadu Governor Banwarilal Purohit still asymptomatic for COVID-19, doing well
3India’s ‘amazing’ support could help bring ‘good news’ to world on rapid COVID-19 testing: Israel